Endocrine Abstracts

Introduction: The treatment with tyrosine-kinase inhibitor drugs (1st line Lenvatinib) in patients with radioiodine-refractory differentiated thyroid cancer (I-131) and disease progression can be burdened by important side effects which often require suspension/reduction of the therapy and correct multidisciplinary management.Patients and methods: Clinical/histopathological characteristics, outcome, adverse events and the role of gender have been evaluat...

Objectives: Differentiated thyroid carcinoma (DTC) in pediatric patients has peculiar clinical, pathological, and molecular characteristics, making its management different from the adult patients. Our study aimed to evaluate the outcome and predictive factors for persistent disease in a large cohort of pediatric patients.Methods: We performed a multicentric Italian study, enrolling patients aged ≤18 years old, diagnosed with a DTC, since January 2...